Jan Brandt‐Jürgens

Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study

Uta Kiltz, Petros P. Sfikakis, Karl Gaffney et al. · Advances in Therapy · 2020 · 38 citations · Full text

Sensitivity and Specificity of Autoantibodies Against <scp>CD</scp>74 in Nonradiographic Axial Spondyloarthritis

E. Riechers, N.T. Baerlecken, Xenofon Baraliakos et al. · Arthritis & Rheumatology · 2018 · 37 citations

Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study

Piotr Wiland, Sławomir Jeka, Eva Dokoupilová et al. · BioDrugs · 2020 · 37 citations · Full text

Tolerability and Patient/Physician Satisfaction with Subcutaneously Administered Methotrexate Provided in Two Formulations of Different Drug Concentrations in Patients with Rheumatoid Arthritis

Ulf Muller-Ladner, Karin Rockwitz, Jan Brandt‐Jürgens et al. · The Open Rheumatology Journal · 2010 · 22 citations · Full text

Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial

Michaela Koehm, Tanja Roßmanith, Ann Christina Foldenauer et al. · The Lancet Rheumatology · 2022 · 17 citations

Rheumatoid Disorder, Rheumatology, Medicine +11